APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES

APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES

Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditionsSeed is led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE)Science originates from three…

Aptadir secures €40M for gene-reactivating RNA drugs - European Biotechnology Magazine

Aptadir Therapeutics has raised €40 million in seed funding to advance an RNA therapy designed to reactivate the gene silenced in Fragile X syndrome.

Milan-based biotech Aptadir Therapeutics raises $45M seed round

AMilan-based biotech company developing novel treatments for difficult to treat genetic conditions has raised a $45m seed round, it said today.Theseed round investment in Aptadir Therapeutics is one o...

4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines

4BIO Capital led upsized and oversubscribed round which includes strategic investment from AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund, reflecting depth of industry interest in this novel RNA therapeutics platform